NDA 217470 · Indivior
Opvee
Nalmefene Hydrochloride · Nasal
Priority reviewLast checked: Nov 19, 2026Latest source record: May 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 22, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
37
9 Phase 3, 2 recruiting
FAERS reports
43
35 serious, 10 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 8, 2026.
OPVEE nasal spray is indicated for the emergency treatment of known or suspected overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. OPVEE nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. OPVEE nasal spray is not a substitute for emergency medical care. OPVEE nasal spray is an opioid antagonist indicated for the emergency treatment of known or suspected overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. OPVEE nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. OPVEE nasal spray is not a substitute for emergency medical care.
Mechanism: OPVEE is an antagonist at opioid receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- OPVEE · NALMEFENE HYDROCHLORIDE EQ 2.7MG BASE/SPRAY · SPRAY, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nalmefene" as an intervention, any sponsor and status, largest first.
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT02364947 · 678 participants · Start Feb 9, 2015 · Primary completion Jul 30, 2016
Drug: Nalmefene hydrochloride; Placebo · For: Alcohol Dependence
Sites: Region, Japan · 7 sites in all
- Efficacy of Nalmefene in Patients With Alcohol DependencePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT00812461 · 678 participants · Start Mar 2009 · Primary completion Mar 2011
Drug: Placebo; Nalmefene · For: Alcohol Dependence
Sites: Assebroek, Belgium; Bruges, Belgium; Charleroi, Belgium · 57 sites in all
- Safety and Efficacy of Nalmefene in Patients With Alcohol DependencePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT00811941 · 665 participants · Start Mar 2009 · Primary completion Nov 2010
Drug: Placebo; Nalmefene · For: Alcohol Dependence
Sites: Litoměřice, Czechia; Lnáře, Czechia; Prague, Czechia · 60 sites in all
- Efficacy of Nalmefene in Patients With Alcohol DependencePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT00811720 · 598 participants · Start Dec 2008 · Primary completion Oct 2010
Drug: Placebo; Nalmefene · For: Alcohol Dependence
Sites: Linz, Austria; Salzburg, Austria; Vienna, Austria · 39 sites in all
- Effect of Nalmefene on the Quality of Resuscitation in Patients Under General AnesthesiaPivotal-lookingCompleted
RenJi HospitalAcademic, hospital or other
NCT04713358 · 542 participants · Start Sep 24, 2021 · Primary completion Dec 31, 2023
Drug: Nalmefene; normal Saline · For: Resuscitation
Sites: Guangxi, China; Shanghai, China; Henan, China · 4 sites in all
- A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol DependencePivotal-lookingCompleted
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT02382276 · 405 participants · Start Jul 13, 2015 · Primary completion Jan 18, 2017
Drug: Nalmefene hydrochloride · For: Alcohol Dependence
Sites: Region, Japan · 7 sites in all
H. Lundbeck A/SIndustry
NCT02195817 · 378 participants · Start Aug 2014 · Primary completion Feb 2016
Drug: Selincro® 18 mg with continuous psychosocial support: Cohort A · For: Alcohol Dependence
Sites: Bécon-les-Granits, France; Bordeaux, France; Cestas, France · 48 sites in all
- NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural AddictionsPivotal-lookingRecruiting
Nantes University HospitalAcademic, hospital or other
NCT05540288 · 266 participants (planned) · Start Mar 31, 2023 · Primary completion Jul 2027
Drug: Nalmefene; Placebo · For: Behavioural Addiction
Sites: Besançon, France; Bordeaux, France; Brest, France · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- coma5
- therapy non-responder5
- bradycardia4
- bradypnoea4
- electrocardiogram qt prolonged4
- hypothermia4
- intentional overdose4
- miosis4
- pneumonia aspiration4
- diabetic ketoacidosis3
- drug withdrawal syndrome3
- nausea3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2010 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 5 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 7 |
| 2025 | 11 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Opvee (Nalmefene HCl)
2024 spending
$7K
Beneficiaries
66
67 claims
Per beneficiary
$99
$47.94 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $6,519 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.
Bahji A, Bach P, Danilewitz M, et al. · J Addict Med 2022 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Pharmacological management of gambling disorder: A systematic review and network meta-analysis.
Ioannidis K, Del Giovane C, Tzagarakis C, et al. · Compr Psychiatry 2025 · Systematic Review, Network Meta-Analysis
- Opioid antagonists for alcohol dependence.
Rösner S, Hackl-Herrwerth A, Leucht S, et al. · Cochrane Database Syst Rev 2010 · Meta-Analysis, Systematic Review
- Opioid antagonists for alcohol dependence.
Srisurapanont M, Jarusuraisin N · Cochrane Database Syst Rev 2000 · Systematic Review
- Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: A systematic review and network meta-analysis.
Kotake K, Hosokawa T, Tanaka M, et al. · Addiction 2024 · Systematic Review, Network Meta-Analysis
- Can alcohol dependent patients adhere to an 'as-needed' medication regimen?
Sinclair J, Chick J, Sørensen P, et al. · Eur Addict Res 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Indivior
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.